United Kingdom

People: Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

1:31pm BST
Change (% chg)

€0.24 (+0.37%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Tellier, Jean-Christophe 

Mr. Jean-Christophe Tellier has served as Chairman of the Executive Committee, Chief Executive Officer, Executive Director of UCB S.A. since January 1, 2015. Before that, he was Member of the Executive Committee, Executive Vice President and President of European Operations of the Company from July 1, 2011. He joined the Company from Ipsen where he was President & General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen's specialty care business in North America, in the areas of endocrinology and neurology. He joined Ipsen in May 2009. He started his career in 1988 in the marketing department of Synthelabo and joined Ciba France as Group Marketing Manager in 1990 and got various marketing & sales position until leading the Marketing & Sales department. In 1997, following the merger of Ciba and Sandoz to form Novartis, he was appointed Head of the Mass Market Business unit in France until the end of 1999 where he became Chief Operating Officer of Novartis France. From 2003 to mid-2006, JC Tellier was Chief Executive Officer (CEO) of Novartis Pharma Belgium and during his tenure was elected president of Pharma.be, the Pharma trade association. At the end of 2006, he was promoted to Head of the Global Arthritis, Bone and Muscle disease Business Franchise at Novartis Headquarters in Basel, Switzerland. In February 2007, he was appointed Chairman and CEO of Novartis Pharma France and Novartis Group France until mid 2008 when he decided to join MacroGenics Inc., a Maryland-based biotechnology company, as Executive Vice President and Chief Commercial Officer. He is physician specialized in rheumatology (University of Paris, France) and followed diverse executive training both at INSEAD and Harvard.

Basic Compensation

Total Annual Compensation, EUR 76,000
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR 1,963,940
All Other, EUR --
Fiscal Year Total, EUR 2,039,940

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --